Early-Phase Oncology Trials Shaping the Future of Cancer Research
Relatively Speaking
Controlling Polysorbate Degradation
Tailored Artificial Intelligence (AI)
From the “AI Pilot Graveyard” to Enterprise- Grade Impact
EDITORIAL SECTION
-
STRATEGY
Smarter Pharma
Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solution
-
CLINICAL TRIALS
Why Clinical Trials Need Digital Endpoints
According Citeline the average success rate for bringing a Phase candidate to market has dropped to an alltime low of just
-
MANUFACTURING
Ensuring Quality and Compliance in Biopharma
Ensuring quality and regulatory compliance in the biopharmaceutical industry is critical to safeguarding product safety and efficacy
-
Information Technology
The Cost of Bad Data
Modern pharmaceutical research generates an unprecedented volume of information Data from genomic sequencing
-
Biopharma
Reimagining Global Biomanufacturing Capacity with Continuous and Modular Systems
Biotechnology is fueling the ongoing expansion of the global market for a broad array of goods
-
EXPERT Talk
Compliance to Competitive Advantage in Pharma Supply
Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser
Advisory Board
.webp)
KNOWLEDGE BANK
-
Articles
Sustainability in Pharma Manufacturing: A Focus on Green Practices
The pharmaceutical industry is pivotal to global healthcare but its manufacturing processes typically carry a significant environmental burden In recent years there has been an increasing recognition of the importance of sustainability in pharmaceutical manufacturing
Building Patient-Centric Clinical Trials: Technologies, Strategies, and Regulatory Considerations
Patientcentricity in clinical trials represents a crucial cultural and operational transformation in the development and evaluation of new treatments The patient experience has evolved from a secondary consideration to a central priority in trial design driven by
Unveiling the Revolutionary Potential: Exploring Blockchain Technology in Pharma
The pharmaceutical industry is renowned for its stringent regulations complex supply chains and crucial emphasis on data integrity In recent years the emergence of blockchain technology has sparked considerable interest
Unleashing the Power of Antimicrobial Peptide Databases: A New Frontier against Antibiotic Resistance
As pathogens continue to evolve and resistance strategies become more sophisticated new solutions are very crucial
mRNA and Oligonucleotide Therapeutics: Emerging Synergies in Genetic Medicine
MRNA therapies work by introducing synthetic mRNA encoding a therapeutic protein enabling transient protein expression that can replace deficient enzymes stimulate immune responses or facilitate gene editing This additive approach is beneficial for diseases caused by lossoffunction mutations or when temporary protein expression is desired
Blockchain in Pharma: Strengthening Drug Traceability, Compliance, and Supply Chain Security
For most of the last decade the European pharmaceutical industry framed supply chain integrity as a packaging problem Put a unique identifier on every pack seal it with an antitampering device check it at the point of dispensing and the falsified medicine threat would be contained Since February that model has been law across the European Union and it has worked better than many sceptics predicte...
-
Techno Trends
Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein
Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue
-
Projects
SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing
SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more
-
Research Insights
A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG
PIGACDG is a congenital disorder of glycosylation caused by pathogenic partial lossoffunction variants in the PIGA gene PIGA encodes an enzyme responsible for the catalytic transfer of Nacetylglucosamine
-
whitepaper
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys
TOP ARTICLES
-
1
Building Patient-Centric Clinical Trials: Technologies, Strategies, and Regulatory Considerations
Dr. Kalpana Katiyar
Ms. Shreeya Arora
Patient-centric clinical studies aim to improve the participant experience, foster diversity, enhance retention, and increase data quality. Advancements in decentralized trial models, digital health t...
-
2
Unveiling the Revolutionary Potential: Exploring Blockchain Technology in Pharma
Sarah Richards
This article explores the transformative potential of blockchain technology in the pharmaceutical industry, addressing challenges such as counterfeit drugs, supply chain inefficiencies, and data manag...
-
3
Unleashing the Power of Antimicrobial Peptide Databases: A New Frontier against Antibiotic Resistance
Dr. Sintu Kumar Samanta
Rajat Kumar Mondal
Debarup Sen
Antimicrobial Peptides (AMPs) offer a promising solution to the global challenge of antimicrobial resistance. AMP databases like APD3, DBAASP, and CAMPR4 hold vital information on these peptides. Howe...
-
4
mRNA and Oligonucleotide Therapeutics: Emerging Synergies in Genetic Medicine
Dr. Prasad Panzade
Messenger RNA (mRNA) and synthetic oligonucleotide therapeutics have emerged as transformative platforms in genetic medicine, enabling modulation of gene expression, correction of pathogenic mutations...
-
5
Blockchain in Pharma: Strengthening Drug Traceability, Compliance, and Supply Chain Security
Lakshmi
Europe’s pharmaceutical supply chain has never been more regulated, more fragmented or more exposed. The Falsified Medicines Directive delivered pack-level verification, but it largely stops at...
press releases Read more...
Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia
Cardiff Oncology Inc a clinicalstage biotechnology company leveraging PLK inhibition to develop novel cancer therapies today announced that the US Food and Drug Administration FDA has granted Orphan Drug Designation to onvansertib for the treatment of patients with chronic myelomonocytic leukemia
Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer
Geneos Therapeutics a clinical stage biotherapeutics company focused on the development of neoantigenbased personalized immunotherapy for cancer PIC today announced the initiation of its Phase randomized clinical trial NCT in patients with highrisk hepatocellular carcinoma HCC liver cancer
Medicovestor Announces FDA Fast Track Designation for MC001, Its First-in-Class Chemoimmunotherapy ADC for Pancreatic Cancer
Medicovestor Inc today announced that the US Food and Drug Administration FDA has granted Fast Track designation to MC its lead investigational firstinclass chemoimmunotherapy antibodydrugconjugate ADC for pancreatic cancer
Orogen Therapeutics Announces Selection of Two Development Candidates for Immune Diseases, Potential Best-in-Class Oral IL-17 and JAK1/TYK2 Small Molecule Inhibitors
Orogen Therapeutics Inc announced the selection of two development candidates DCs ORO and ORO potential bestinclass oral small molecule inhibitors of IL and JAKTYK respectively Both DCs have completed extensive nonclinical studies to demonstrate attractive
Events Read more...
21 - 23
Oct 2026Drug Formulation & Drug Delivery 2026
Paris, France
21 - 22
Oct 2026Advance Clinical Trials and Research 2026
Paris, France
22 - 23
Oct 2026PDA Aseptic Symposium 2026
Congress Square Nakanoshima, O...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
27 - 28
Oct 2026Pharma Manufacturing & Automation Convention 2026
Novotel Hyderabad Airport, Ind...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
LATEST NEWS Read more...
AI Proteins Announces Research Collaboration and License Agreement With Astellas Pharma to Discover and Develop Novel Miniprotein-Based Therapeutics Valued at Over $400 Million
AI Proteins Inc a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins today announced it has entered into a Research Collaboration and License Agreement with Astellas Innovation Management LLC an affiliate of Astellas Pharma Inc TSE to discove...
Okomera Announces Trade Agreement with Servier to Use Tumor Miniaturization Technology in Cancer Research
Okomera a TechBio company that personalizes cancer management with its technology combining minivatars tumor microfluidics and AI imaging today announced the signing of a commercial agreement with Servier an independent international pharmaceutical group
ScionxBio Announces Collaboration to Develop Long-Acting xRNA Therapeutics
ScionxBio a privately held preclinicalstage biotechnology company pioneering nextgeneration mRNA therapeutics distinguished by their extended durability profile today announced that it has entered into a worldwide strategic collaboration and licensing agreement with Sanofi
Takara Bio USA Partners with SPT Labtech to Deliver Automation-Ready NGS Library Preparation Technologies
Takara Bio USA Inc a wholly owned subsidiary of Takara Bio Inc and SPT Labtech today announced their partnership to deliver validated automated library preparation workflows that combine Takara Bio nextgeneration sequencing NGS library preparation chemistries with SPT Labtechs firefly liquid handlin...
AtomVie Global Radiopharma Announces Strategic Partnership with Jubilant Radiopharma to Strengthen Logistics and Distribution in Clinical Trials
AtomVie Global Radiopharma a global contract developer and manufacturer CDMO for radiopharmaceuticals today announced a strategic partnership with Jubilant DraxImage Inc operating as Jubilant Radiopharma Jubilant Radiopharma to provide logistics approval and lastmile distribution services to support
Transcripta Bio Announces Research Collaboration to Advance Discovery of New ALS Treatments
Transcripta Bio an AIpowered drug discovery company focused on neurological and neuromuscular diseases today announced a research collaboration and licensing agreement with Mayo Clinic centered on amyotrophic lateral sclerosis ALS a fatal neurodegenerative disease with few effective treatments
